Delivery Order SPE2DB24D1205-SPE2DB25FCZWZ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units valued at $1,094.38 with a firm fixed price structure. This non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for this delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,678.14 for Xyosted 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed-price, non-set-aside delivery order will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies, valued at $1,308.97, with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by November 18, 2025. The product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials with a ceiling value of $1,150.40. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of October 23, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of October 16, 2025. This competitive award, issued on October 15, 2025, utilizes firm fixed pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector medication with a contract ceiling value of $2,476.04. This firm fixed-price delivery order, which extends through August 29, 2025, represents a pediatric or adult testosterone replacement therapy product to support federal medical supply requirements. The contract was competitively awarded without a set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector vials valued at $1,789.66. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded a $1,455.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a completion date of November 5, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract will be performed at the...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZWZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units with a ceiling value of $1,346.07. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by August 27, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, leverages this prime IDV to supply a broad spectrum of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to fulfill federal medical procurement requirements through open competition, combined with its extensive portfolio of delivery orders covering diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical devices, positions it as a critical vendor within the federal supply chain. This particular delivery order for testosterone replacement therapy auto-injectors reflects the company's ongoing role in supporting military personnel healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/26/25 |